Which hedge funds own SPRY? ARS PHARMACEUTICALS INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
7 of the hedge funds tracked by WhaleCreep disclosed a position in SPRY (ARS PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $188.3m in total. The largest holder by portfolio weight is RA Capital Management at 0.8% of its book. 1 manager opened a new position this quarter: Tudor Investment. 2 exited: Brevan Howard Capital Management, D. E. Shaw & Co.
7tracked managers holding
1opened this quarter
2exited this quarter
Which hedge funds hold SPRY? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| RA Capital Management | Q2 2026 | 0.8% | $87.0m | 10,860,977 | 0% | held |
| Rubric Capital Management | Q2 2026 | 0.6% | $68.4m | 8,540,861 | 7% | added |
| Third Point | Q2 2026 | 0.2% | $8.0m | 1,000,000 | 0% | held |
| Millennium Management | Q2 2026 | 0.0% | $19.2m | 2,400,937 | -60% | reduced |
| Citadel Advisors | Q2 2026 | 0.0% | $4.3m | 531,063 | -70% | reduced |
| Tudor Investment | Q2 2026 | 0.0% | $367.6k | 45,895 | – | new |
| Marshall Wace | Q2 2026 | 0.0% | $990.9k | 123,714 | 18% | added |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Brevan Howard Capital Management | 0.0% | $373.9k |
| D. E. Shaw & Co | 0.0% | $95.3k |
How has hedge fund ownership of SPRY changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 7 | $188.3m |
| Q1 2026 | 8 | $223.1m |
| Q4 2025 | 5 | $225.6m |
| Q3 2025 | 4 | $172.0m |
| Q2 2025 | 4 | $219.8m |
| Q1 2025 | 3 | $157.1m |
| Q4 2024 | 3 | $126.5m |
| Q3 2024 | 5 | $180.3m |
| Q2 2024 | 4 | $101.3m |
| Q1 2024 | 4 | $121.8m |
| Q4 2023 | 4 | $59.3m |
| Q3 2023 | 4 | $41.9m |
| Q2 2023 | 4 | $45.4m |
| Q1 2023 | 6 | $48.6m |
| Q4 2022 | 5 | $64.7m |
| Q3 2022 | 3 | $20.2m |
Counts every tracked manager that disclosed SPRY in that quarter's filing, including managers that have since stopped filing.